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Introduction: Thymidine kinase 1 (TK1) is a metabolic enzyme 
involved in DNA synthesis. Most standard treatment protocols for 
lung cancer (LC) include cytotoxic agents, which are potential modu-
lators of TK1. We aimed to assess the prognostic significance of serum 
TK1 activity and its role in monitoring chemotherapy in LC patients.
Methods: TK1 activity was measured using the DiviTum (Biovica) 
assay in sera from 233 patients with non–small-cell lung cancer 
(NSCLC), 91 with small-cell lung cancer (SCLC), and 90 with 
benign lung disease.
Results: TK1 activity was significantly associated with age, perfor-
mance status, and stage in NSCLC and with stage and weight loss in 
SCLC. In multivariate analysis, pretreatment TK1 activity, adjusted 
for performance status, stage, and weight loss, independently affected 
survival in NSCLC (relative risk =1.45, p = 0.031) and SCLC (rela-
tive risk = 2.49, p = 0.001). In NSCLC patients, adjusted elevated 
TK1 activity (>100 Du/L) at pretreatment was a significant predictor 
of treatment failure (odds ratio = 2.55, p = 0.01). A small (less than 
twofold) increase in TK1 activity after the first and second cycle of 
chemotherapy was significantly associated with treatment failure and 
poor overall survival.
Conclusions: Elevated pretreatment serum TK1 activity was an 
independent, adverse prognostic factor, based on survival, in the two 
main histological types of LC. A small (less than twofold) increase 
in TK1 activity after the first and second cycle of chemotherapy was 
associated with treatment failure and poor overall survival.
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One of the most important biological mechanisms of cancer aggressiveness is related to uncontrolled tumor 
proliferation; its markers have been shown to have prognos-
tic value when measured in lung cancer (LC) patients.1,2 To 
take these measurements, however, a biopsy or resection 
may be required. One such marker is thymidine kinase 1 
(TK1), which is the key cytosolic enzyme in the salvage 
pathway for deoxythymidine monophosphate (dTMP) syn-
thesis; because TK1 is involved in DNA synthesis, it is con-
sidered a marker for cell proliferation. Notably, dividing 
cells release TK1 during mitotic exit, which is mediated by 
the ubiquitin system.3 Thus, TK1 activity can be detected in 
the serum.
Recently, a new highly sensitive assay for the mea-
surement of TK activity in serum has been developed that 
is based on immobilization of the phosphorylated reaction 
product by incorporation into DNA.4 Korkmaz et al.5 evalu-
ated this assay in a small group of 48 patients with advanced 
non–small-cell lung cancer (NSCLC) and found a signifi-
cant correlation between serum TK1 activity and primary 
tumor maximum standardized uptake, based on 18-fluoro-
deoxyglucose positron emission tomography scans, and 
overall survival. The present study was aimed to assess the 
prognostic significance of the new TK1 assay in the two 
main histological types of LC, NSCLC and small-cell lung 
cancer (SCLC).
Although TK1 levels detected in the serum primarily 
reflect proliferative activity, this enzyme is an important ele-
ment of a complex system of kinases in the salvage pathway, 
complementing the main de novo pathway of dTMP syn-
thesis. The activities of the two pathways are coordinated 
with the transport systems of nucleosides.6 There are many 
factors modifying these systems. Most standard treatment 
protocols for LC include cytotoxic agents that are poten-
tial modulators of TK1 activity.6–8 Therefore, we investi-
gated the usefulness of this assay to monitor treatment with 
these agents.
METHODS AND PATIENTS
This prospective study was performed on consecutive 
patients between November 1, 2008, and October 30, 2013. It 
was approved by the Institutional Ethical Review Board (0441-
08-HMO) and included 90 patients with benign lung disease 
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(BLD), 233 patients with NSCLC, and 91 patients with SCLC. 
The diagnoses of all lung tumors were confirmed pathologically.
After informed consent was given, serum samples were 
obtained from all patients, before the start of treatment, and stored 
at –80°C until analysis. Serum TK1 activity was measured with a 
colorimetric enzyme-linked immunosorbent assay kit (DiviTum; 
Biovica International AB, Uppsala, Sweden), as described previ-
ously.9 TK1 levels were expressed in DiviTum units/L (Du/L).
TABLE 1.  Distribution of TK1 Activity in Patients With Benign Lung Disease or Lung Cancer
Study group n
Serum TK1 activity (Du/L)
Mean Median IQR
95th 
Percentile p valuea
All LC vs. BLD p <0.001
  BLD 90 188 74 29–186 855
  All LC 324 819 155 59–479 3481
All non—small-cell lung carcinoma 233 468 129 56–344 1,484
Age (yr) p = 0.001
  ≤62 112 509 178 76–514 1,593 
  >62 121 424 101 36–241 1,307
Gender p = 0.259 
  Male 151 578 148 60–397 1,705
  female 82 266 111 42–303 1,135
Smoking habits p = 0.561 
  Nonsmoker 70 929 131 54–410 2, 184 
  Smoker/ex-smoker 163 332 129 58–289 1, 496 
Histological type p = 0.571 
  Adenocarcinoma 145 536 108 46–341 1,450
  Squamous 59 393 181 60–358 1,520
  Other 29 283 135 42–336 1,509
Performance status p = 0.024 
  0–1 190 302 114 56–292 1,348
  ≥2 43 1216 222 82–697 3,138
Weight loss (kg) p = 0.469 
  ≤5 94 518 115 58–325 1, 407 
  >5 139 400 150 55–373 2, 083 
TNM stage p <  0.001 
  I–II 39 153 82 31–152 1, 158 
  III 66 234 116 57–224 1, 213 
  IV 128 653 181 63–514 1, 711 
All small-cell lung carcinoma 91 1,717 325 85–1478 6,132 
Age p = 0.278 
  ≤62 44 1, 986 423 102–1555 5, 947 
  >62 47 1, 465 195 64–1477 9, 795 
Gender p = 0.118 
  Male 66 2,148 398 95–2,273 10,086
  female 25 577 115 76–697 4, 036 
Performance status p = 0.177 
  0–1 54 1, 276 181 60–1,127 6, 104 
  ≥2 37 2, 298 414 98–1,883 14,586
Weight loss (kg) p = 0.013 
  ≤5 56 1, 018 159 50–843 5, 629 
  >5 35 2, 828 467 126–3,090 19,195
Stage p = 0.007 
  Limited 32 362 139 82–400 2, 160 
  Extensive 59 2, 452 535 95–3,090 12,124
IQR, interquartile range; TK1, thymidine kinase 1; BLD, benign lung disease; LC, lung cancer.
ap values derived from Kruskal-Wallis and Mann-Whitney tests.
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Two tumor response categories were applied: progres-
sive disease (PD) and nonprogression (NP), including com-
plete remission, partial response, and stable disease.
Statistical Methods
Kruskal-Wallis, Mann-Whitney, Wilcoxon, Spearman’s 
correlation, fisher’s exact test, logistic regression, Kaplan-
Meier, and Cox survival models, and receiver operating char-
acteristic curves were used for statistical analyses.
RESULTS
TK1 Activity Assay in NSCLC
Patients with both NSCLC and SCLC showed signifi-
cantly higher TK1 activities compared with those with BLD 
(medians 129 and 325 versus 74 Du/L; p = 0.003 and p < 
0.001, respectively). furthermore, patients with SCLC had a 
higher TK1 activity than those with NSCLC (p = 0.017). A 
cutoff value between low- and high-serum TK1 was set at 100 
Du/L—the closest point on the receiver operating character-
istic curve to the optimal sensitivity and specificity in the LC 
(NSCLC + SCLC) versus BLD model.
In NSCLC (Table 1), the serum TK1 activity was asso-
ciated with age, performance status (PS), and disease stage. 
Median survival for patients with normal versus elevated TK1 
activity was 18.6 versus 9.0 months, respectively (p = 0.001, 
fig. 1A). Multivariate analysis (Table 2) selected PS, disease 
stage, weight loss (WL), and serum TK1 as the most impor-
tant pretreatment characteristics with independent impacts on 
survival.
Of 233 patients with NSCLC, 199 were treated with che-
motherapy. The pretreatment activity of TK1 in PD patients 
(n = 74) was significantly higher than that in NP patients (n = 
125) (median 183 versus 105 Du/L, respectively, p = 0.005). In 
the logistic regression, the elevated TK1 activity (>100 Du/L), 
adjusted for stage, PS, and WL, was a significant predictor 
of treatment failure (odds ratio [OR] = 2.55, 95% confidence 
interval, 1.25–5.22).
TK1 Activity Assay in SCLC
In SCLC, TK1 levels were associated (Table 1) with dis-
ease stage and WL. The median survival for patients with nor-
mal TK1 activity was longer than that for those with elevated 
levels (16.5 versus 8.3 months, respectively, p = 0.003, fig. 1B). 
In multivariate analysis, PS, WL, and serum TK1 indepen-
dently affected survival (Table 2).
Eighty-five of 91 patients were treated with chemother-
apy. The basal TK1 activity in PD patients (n = 21, median 
730 Du/L) was higher than that in NP patients (n = 64, median 
197 Du/L, p = 0.041). The elevated TK1 activity did not reach 
statistical significance for the prediction of treatment failure 
(OR = 1.95, p = 0.09).
TK1 Activity Assay in Monitoring 
Chemotherapy
Patients receiving platinum-based therapy, combined 
with pemetrexed (n = 43), gemcitabine (n = 13), vinorelbine (n 
= 22), and etoposide (n = 18), were monitored before the first 
(basal), second, and third cycles of chemotherapy. A signifi-
cant increase in TK1 activity was observed after the first and 
second cycles for all applied regimens (Table 3). However, the 
increase was larger for pemetrexed and gemcitabine (medians, 
second/first ratio: 6.3 and 8.1, respectively; medians, third/
first ratio: 12.4 and 22.8, respectively) compared with vinorel-
bine and etoposide (medians, second/first ratio: 1.5 and 2.2, 
respectively; medians, third/first ratio: 1.8 and 1.9, respec-
tively). Patients were divided into two groups: (1) treated with 
pemetrexed or gemcitabine and (2) treated with vinorelbine 
or etoposide. TK1 activity significantly increased in PD and 
FIGURE. 1.  Survival for 233 patients 
with non–small-cell lung cancer (A) 
and 91 patients with small-cell lung 
cancer (B). Kaplan-Meier estimates 
according to pretreatment serum TK1 
activity. TK1, thymidine kinase.
TABLE 2.  Multivariate Cox’s Regression: Relative Risk in 
Patients with NSCLC (n = 233) or SCLC (n = 91)
Characteristics
Relative 
risk 95% CI p value
NSCLC
  Performance status (0–1 vs.  ≥2) 3.53 2.35–5.29 < 0.001
  Weight loss (no vs.  yes) 1.63 1.16–2.28 0.005
  Stage (M0 vs.  M1) 2.14 1.53–2.98 < 0.001
  TK1 (≤100 Du/L vs.  > 100 Du/L) 1.45 1.04–2.02 0.031
SCLC
  Performance status (0–1 vs.  ≥2) 1.83 1.11–3.02 0.018
  Weight loss (no vs.  yes) 1.77 1.07–2.92 0.026
  Stage (limited vs.  >  extensive) 1.39 0.80–2.43 0.241
  TK1 (≤100 Du/L vs.  > 100 Du/L) 2.49 1.41–4.41 0.001
CI, confidence interval; TK1, thymidine kinase 1; NSCLC, non–small-cell lung 
cancer; SCLC, small-cell lung cancer.
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NP patients in both groups after the first and second cycles of 
chemotherapy (Table 4). However, this increase was smaller 
in PD patients than in NP patients, with the exception of one 
subset of patients in the NP group after the first cycle of plati-
num with vinorelbine or etoposide. After the second cycle, the 
ratio in this NP group reached 3.
The study population was split in two groups according 
to the increase in TK1 activity, using a cutoff of 2.0 (overall 
median increase in PD patients for all regimens). The increase 
was more than twofold after the first cycle of chemotherapy 
in 12 of 27 PD patients (44%) and in 49 of 69 NP patients 
(71%) (p = 0.021). After the second cycle, a more than two-
fold increase occurred in eight of 23 PD patients (38%) and 
58 of 73 NP patients (80%) (p = 0.003). Patients with more 
than a twofold increase in TK1 activity after the first (fig. 2A) 
and second (fig. 2B) cycles of chemotherapy showed signif-
icantly longer median survival compared with those with a 
less than or equal to twofold increase (17.5 versus 9.9 months, 
p = 0.023 and 19.6 versus 8.3 months, p = 0.002, respectively).
We analyzed relationship between TK1 activity and 
WBC account during chemotherapy. Spearman’s correlation 
coefficients at regimens containing pemetrexed, gemcitabine, 
vinorelbine, and etoposide were 0.13 (p = 0.202), 0.26 
(p = 0.09), 0.43 (p = 0.003), and 0.45 (p = 0.007), respectively.
DISCUSSION
The pretreatment serum TK1 activity detected in this 
study reflects the overall condition (proliferative background) 
of each individual. The TK1 activity of the lung tumor and 
its contribution to measured TK1 activity in serum remain 
unknown. The higher TK1 activity of LC patients versus that 
of BLD is conceivably due to the higher proliferation of LC. 
The significant associations of TK1 activity with tumor bur-
den both in NSCLC and in SCLC may indicate, at least in 
part, its tumor origin.
The DiviTum assay explored in this study demonstrated 
the clinical importance of measuring TK1 activity as a prog-
nostic marker in NSCLC and SCLC. In both subtypes of LC, 
elevated TK1 predicted poor survival after the adjustment for 
disease stage, WL, and PS. The present study is consistent 
with a previous, retrospective study on TK1 activity, measured 
by radioenzyme immunoassay.10 The authors of that study 
pointed to the promising prognostic value of pretherapeutic 
TK for overall survival in multivariate analyses of NSCLC 
patients. Moreover, we showed that elevated pretreatment TK1 
activity in NSCLC, after adjustment for stage, PS, and WL, 
remains a significant predictor of treatment failure with an OR 
of 2.55.
We find that platinum-based combinations with peme-
trexed, gemcitabine, vinorelbine, and etoposide induced a 
significant increase in TK1 activity. However, the strongest 
increase was observed in regimens that included peme-
trexed or gemcitabine, whereas a less pronounced effect was 
observed in those that included etoposide or vinorelbine. 
Topolcan et al.11 previously observed an increase in TK1 
activity in colorectal cancer during chemotherapy with regi-
mens that included 5-fluorouracil (5-fU).
Cytotoxic agents, such as pemetrexed, gemcitabine 
(through its metabolite, difluorodeoxyuridine monophos-
phate), and 5-fU, are strong inhibitors of thymidylate syn-
thase and the de novo pathway of dTMP synthesis.6,12,13 To 
overcome this effect, cells up-regulate the compensating sal-
vage pathway for dTMP synthesis. The increased activity of 
the salvage pathway leads to an increased uptake of thymidine 
TABLE 4.  Changes in TK1 Activity After the First and Second Cycles of Chemotherapy According to Response
Platinum/pemetrexed or gemcitabine Platinum/vinorelbine or etoposide
Response PD NP PD NP
Number 11 45 16 24
2nd/1st ratio (median, IQR)
p value (2nd vs. 1st)a
3rd/1st ratio (median, IQR)
p value (3rd vs. 1st)
2.1, 1.3–15.4
0.003
1.9, 1.2–20.4
0.028
6.1, 1.4–15.4
<0.0001
6.9, 2.8–36.5
<0.0001
2.1, 1.5–4.7
0.030
1.5, 1.2–1.7
0.043
1.7, 1.17–10.3
0.004
3.0, 1.3–14.3
0.010
TK1, thymidine kinase 1; 1st, 2nd, 3rd, TK1 activity measured before first (basal), second, and third cycles of chemotherapy, respectively; PD, progressive disease; NP, nonprogressive; 
IQR, interquartile range.
ap values were derived from the Wilcoxon signed-rank test.
TABLE 3.  Changes in TK1 Activity After the First and Second Course of Chemotherapy, According to Regimen
Platinum-based regimen with Pemetrexed Gemcitabine Vinorelbine Etoposide
Histology NSCLC NSCLC NSCLC SCLC
Number 43 13 22 18
2nd/1st ratio (median, IQR)
ap value (2nd vs. 1st)
3rd/1st ratio (median, IQR)
p value (3rd vs. 1st)
6.3, 3.6–20.6
<0.0001
12.4, 5.0–38.6
<0.0001
8.1, 4.7–30.3
0.003
22.8, 6.2–53.3
0.008
1.5, 1.1–2.4
0.028
1.8, 1.2–3.4
0.026
2.2, 1.2–11.0
0.008
1.9, 1.1–14.0
0.028
TK1, thymidine kinase 1; 1st, 2nd, 3rd, TK1 activity measured before first (basal), second, and third cycles of chemotherapy, respectively; IQR, interquartile range; NSCLC, 
non–small-cell lung cancer; SCLC, small-cell lung cancer.
ap values were derived from the Wilcoxon signed-rank test.
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through activation of the membrane equilibrative nucleoside 
transporter 1 (ENT1) delivery system.6,14,15 Recent experimen-
tal data obtained with HeLa cells that highly express ENT1 
demonstrated that etoposide was a strong inducer of ENT1 
activity and TK1 expression.8 Activation of the salvage TK 
pathway and/or the ENT1 system appears to be the main factor 
explaining increased TK1 activity after treatment with peme-
trexed-, and gemcitabine-, or etoposide-containing regimens. 
At these conditions, TK1 behaves as a metabolic marker, 
reflecting changes in two pathways of dTMP synthesis.
The increase of serum TK1 activity during chemother-
apy may result from metabolic changes both in tumor and nor-
mal tissues. This is confirmed by the observation of increased 
TK1 activity at the use of 5-fU-containing regimens in adju-
vant setting in colon cancer patients.11 The overall increase 
of TK1 activity might include for example the replication 
effect from leukocyte. Higher increase denotes higher recov-
ery of the leukocytes and might contribute a better treatment 
response to treatment. This mechanism might be important at 
the use of vinorelbine and etoposide. Actually, at these regi-
mens, we observed a better correlation between the TK1 activ-
ity and WBC counts during chemotherapy (r = 0.43–0.45).
We found that the extent of increase in TK1 activity at 
the beginning of LC treatment may predict its effectiveness and 
prognosis. An analysis of changes during chemotherapy showed 
that a more than twofold increase in enzyme activity was more 
often found in NP patients than in PD patients after the first 
and second cycles of chemotherapy. Survival analysis also 
showed longer survival for patients who had more than a two-
fold increase in TK1 activity after either the first or the second 
cycle of chemotherapy. Thus, monitoring by TK1 early during 
chemotherapy could provide valuable information for detection 
of nonresponders, thereby preventing unnecessary toxicity.
Our results show that the difference between two response 
groups was evident already after the first cycle of treatment with 
regimens containing thymidylate synthase–blocking agents: 
pemetrexed and gemcitabine. Other mechanisms appear to be 
responsible for the TK1 activity change at the use of etoposide/
vinorelbine, and this may be a reason for delaying increase, 
which has become evident only after the second cycle.
further studies are needed to reveal and describe addi-
tional factors contributing to overall TK1 condition during 
chemotherapy and improving associative models.
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FIGURE. 2.  Kaplan-Meier estimates 
according to the ratio between 
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